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The suppression of tumorigenicity 2/IL-33 (ST2/IL-33) pathway has been implicated in several immune and 
inflammatory diseases. ST2 is produced as 2 isoforms. The membrane-bound isoform (ST2L) induces an 
immune response when bound to its ligand, IL-33. The other isoform is a soluble protein (sST2) that is thought 
to be a decoy receptor for IL-33 signaling. Elevated sST2 levels in serum are associated with an increased risk 
for cardiovascular disease. We investigated the determinants of sST2 plasma concentrations in 2,991 Framing-
ham Offspring Cohort participants. While clinical and environmental factors explained some variation in 
sST2 levels, much of the variation in sST2 production was driven by genetic factors. In a genome-wide associ-
ation study (GWAS), multiple SNPs within IL1RL1 (the gene encoding ST2) demonstrated associations with 
sST2 concentrations. Five missense variants of IL1RL1 correlated with higher sST2 levels in the GWAS and 
mapped to the intracellular domain of ST2, which is absent in sST2. In a cell culture model, IL1RL1 mis-
sense variants increased sST2 expression by inducing IL-33 expression and enhancing IL-33 responsiveness 
(via ST2L). Our data suggest that genetic variation in IL1RL1 can result in increased levels of sST2 and alter 
immune and inflammatory signaling through the ST2/IL-33 pathway.
Introduction
Suppression of tumorigenicity 2 (ST2) is a member of the IL-1 
receptor (IL-1R) family that plays a major role in immune and 
inflammatory responses. Alternative promoter activation and 
splicing produces both a membrane-bound protein (ST2L) and 
a soluble form (sST2) (1). The transmembrane form of ST2 is 
selectively expressed on Th2- but not Th1-type T cells, and bind-
ing of its ligand, IL-33, induces Th2 immune responses (2, 3). 
In contrast, the soluble form of ST2 acts as a decoy receptor by 
sequestering IL-33 (4). The IL-33/ST2 pathway has important 
immunomodulatory effects (2, 3).
Clinically, the ST2/IL-33 signaling pathway participates in the 
pathophysiology of a number of inflammatory and immune 
diseases related to Th2 activation, including asthma (5), ulcera-
tive colitis (6), and inflammatory arthritis (7). ST2 expression is 
also upregulated in cardiomyocytes in response to stress (8) and 
appears to have cardioprotective effects in experimental studies 
(9, 10). As a biomarker, circulating sST2 concentrations have been 
linked to worse prognosis in patients with heart failure (11–15), 
acute dyspnea (16), and acute coronary syndrome (17, 18) and also 
predict mortality and incident cardiovascular events in individuals 
without existing cardiovascular disease (19).
Both sST2 and its transmembrane form are encoded by IL-1R–
like 1 (IL1RL1). Genetic variation in this pathway has been linked 
to a number of immune and inflammatory diseases (20). The 
contribution of IL1RL1 locus variants to interindividual variation 
in sST2 has not been investigated. The emergence of sST2 as an 
important predictor of cardiovascular risk and the important role 
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of the ST2/IL-33 pathway in inflammatory diseases highlight the 
value of understanding genetic determinants of sST2. The fam-
ily-based FHS cohort provides a unique opportunity to examine 
the heritability of sST2 and to identify specific variants involved 
using a genome-wide association study (GWAS). Thus, we per-
formed a population-based study to examine genetic determinants 
of sST2 concentrations, coupled with experimental studies to elu-
cidate the underlying molecular mechanisms.
Results
Clinical characteristics of the 2,991 FHS participants are presented 
in Supplemental Table 1 (supplemental material available online 
with this article; doi:10.1172/JCI67119DS1). The mean age of 
participants was 59 years, and 56% of participants were women. 
Soluble ST2 concentrations were higher in men compared with 
those in women (P < 0.001). Soluble ST2 concentrations were 
positively associated with age, systolic blood pressure, body-mass 
index, antihypertensive medication use, and diabetes mellitus 
(P < 0.05 for all). Together, these variables accounted for 14% of the 
variation in sST2 concentrations. The duration of hypertension or 
diabetes did not materially influence variation in sST2 concentra-
tions. After additionally accounting for inflammatory conditions, 
clinical variables accounted for 14.8% of sST2 variation.
Heritability of sST2. The age- and sex-adjusted heritability (h2) of 
sST2 was 0.45 (P = 5.3 × 10–16), suggesting that up to 45% of the vari-
ation in sST2 not explained by clinical variables was attributable to 
genetic factors. Multivariable adjustment for clinical variables pre-
viously shown to be associated with sST2 concentrations (21) did 
not attenuate the heritability estimate (adjusted h2 = 0.45, P = 8.2 
× 10–16). To investigate the influence of shared environmental fac-
tors, we examined the correlation of sST2 concentrations among 603 
spousal pairs and found no significant correlation (r = 0.05, P = 0.25).
Genetic correlates of sST2. We conducted a GWAS of 
circulating sST2 concentrations. Quantile-quantile, 
Manhattan, and regional linkage disequilibrium 
plots are shown in Supplemental Figures 1–3. There 
were 388 SNPs associated with sST2 concentrations 
at P < 5 × 10–8, all on chromosome 2q12.1 (Supple-
mental Table 2). All genome-wide significant SNPs 
were located in a 400-kb linkage disequilibrium block 
that included IL1RL1 (the gene encoding ST2), IL1R1, 
IL1RL2, IL18R1, IL18RAP, and SLC9A4 (Figure 1). 
Results for 11 genome-wide significant “indepen-
dent” SNPs, defined as pairwise r2 < 0.2, are shown 
in Table 1. In aggregate, these 11 “independent” 
genome-wide significant SNPs across the IL1RL1 
locus accounted for 36% of heritability of sST2. In 
conditional analyses, 4 out of the 11 SNPs remained 
genome-wide significant, independent of each other 
(rs950880, rs13029918, rs1420103, and rs17639215), 
all within the IL1RL1 locus. The most significant SNP 
(rs950880, P = 7.1 × 10–94) accounted for 12% of the 
residual interindividual variability in circulating 
sST2 concentrations. Estimated mean sST2 concen-
trations were 43% higher in major homozygotes (CC) 
compared with minor homozygotes (AA). Three loci 
Table 1
Genome-wide significant SNPs (with r 2 < 0.2) associated with sST2
Chr SNP Position Location Nearest Allele MAF βA s.e. P 
  (NCBI 36.3) relative to gene gene(s) (major/minor)
2 rs950880 102298994 Intron IL1RL1 C/A 0.39 –0.18 0.01 7.11E-94
2 rs13029918 102323723 Intron, splice site IL1RL1 A/G 0.05 –0.29 0.02 1.54E-39
2 rs1420103 102315064 Intron IL1RL1 C/A 0.23 0.13 0.01 1.01E-35
2 rs1014286 102515532 nSNP SLC9A4 A/G 0.36 0.11 0.01 2.61E-33
2 rs17639215 102319876 Intron IL1RL1 G/A 0.13 0.15 0.01 1.71E-30
2 rs12999542 102331824 Intron IL1RL1 A/C 0.11 –0.15 0.01 2.08E-27
2 rs13019803 102142634 Intron IL1R1 C/T 0.11 –0.14 0.02 5.95E-20
2 rs1558648 102176600 Intron IL1RL2 T/G 0.12 –0.13 0.02 3.94E-16
2 rs2302612 102218140 nSNP IL1RL2 T/C 0.17 –0.08 0.01 2.08E-11
2 rs11693697 102282094 Intergenic IL1RL1 T/C 0.22 –0.08 0.01 6.81E-11
2 rs11465699 102421199 Intron IL18RAP G/A 0.06 0.14 0.02 1.64E-08
Aβ estimate represents estimated change in log-sST2 per minor allele. Chr, chromosome; MAF, minor allele frequency; β, β estimate; SLC9A4, solute carrier 
family 9 member 4; IL1R1, IL-1R, type I; IL1RL2, IL-1R–like 2.
Table 2
Expression-associated SNPs
eSNP sST2 P Tissue eSNP P Transcript
rs10515921 1.85E-25 Blood 2.40E-33 IL18RAP
   9.10E-06 IL18R1
rs13001325 8.64E-94 Cerebellum 1.46E-09 IL18R1
   1.54E-05 IL1RL1
rs13001325 8.64E-94 Prefrontal cortex 1.95E-12 IL1RL1
   2.99E-12 IL18R1
rs13001325 8.64E-94 Visual cortex 4.77E-10 IL18R1
   1.85E-07 IL1RL1
rs1420101 4.33E-92 Adipose 2.53E-05 IL18R1
rs1420101 4.33E-92 Blood 2.08E-20 IL18RAP
rs1420101 4.33E-92 Lymphocytes 5.05E-06 IL18R1
rs1420101 4.33E-92 CD4+ lymphocytes 5.01E-04 IL18R1
rs1420101 4.33E-92 Blood 5.50E-04 IL18R1
rs1946131 2.21E-27 Blood 8.50E-41 IL18RAP
   9.40E-11 IL18R1 
rs741285 2.61E-33 Blood 2.60E-20 IL18RAP
   7.00E-09 IL18R1
Pairwise linkage disequilibrium with top 10 sST2 loci: rs10515921 and rs17639215  
(r2 = 0.94); rs13001325 and rs950880; rs1420101 and rs950880; rs1946131 and 
rs12999542; rs741285 and rs1014286 (r2 = 1.0 for all).
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outside of the IL1RL1 locus had suggestive associations with sST2 
(P < 1 × 10–6) and are displayed in Supplemental Table 3.
In silico association with expression SNPs. The top 10 sST2 SNPs 
(among 11 listed in Table 1) were explored in collected gene 
expression databases. There were 5 genome-wide significant 
sST2 SNPs associated with gene expression across a variety of 
tissue types (Table 2). Specifically, rs13001325 was associated 
with IL1RL1 gene expression (the gene encoding both soluble 
and transmembrane ST2) in several subtypes of brain tissue 
(prefrontal cortex, P = 1.95 × 10–12; cerebellum, P = 1.54 × 10–5; 
visual cortex, P = 1.85 × 10–7). The CC genotype of rs13001325 was 
associated with a higher IL1RL1 gene expression level as well as a 
higher circulating sST2 concentration when compared with the 
TT genotype (Supplemental Figure 4). Other ST2 variants were 
significantly associated with IL18RAP (P = 8.50 × 10–41, blood) and 
IL18R1 gene expression (P = 2.99 × 10–12, prefrontal cortex).
In silico association with clinical phenotypes in published data. The 
G allele of rs1558648 was associated with lower sST2 concentra-
tions in the FHS (0.88-fold change per G allele, P = 3.94 × 10–16) 
and higher all-cause mortality (hazard ratio [HR] 1.10 per G allele, 
95% CI 1.03–1.16, P = 0.003) in the CHARGE consortium, which 
observed 8,444 deaths in 25,007 participants during an average fol-
low-up of 10.6 years (22). The T allele of rs13019803 was associated 
with lower sST2 concentrations in the FHS (0.87-fold change per 
G allele, P = 5.95 × 10–20), higher mortality in the CHARGE consor-
tium (HR 1.06 per C allele, 95% CI 1.01–1.12, P = 0.03), and higher 
risk of coronary artery disease (odds ratio 1.06, 95% CI 1.00–1.11, 
P = 0.035) in the CARDIoGRAM consortium, which included 
22,233 individuals with coronary artery disease and 64,762 controls 
(23). In relating sST2 SNPs to other clinical phenotypes (including 
blood pressure, body-mass index, lipids, fasting glucose, natriuretic 
peptides, C-reactive protein, and echocardiographic traits) in pre-
viously published studies, we found nominal associations with 
C-reactive protein for 2 SNPs (Supplemental Table 4).
Putative functional variants. Using GeneCruiser, we examined 
nonsynonymous SNPs (nSNPs) (missense variants) that had 
at least suggestive association with sST2 (P < 1 × 10–4), includ-
ing SNPs that served as proxies (r2 = 1.0) for nSNPs within the 
1000 Genomes Pilot 1 data set (ref. 24 and Table 3). There were 
6 missense variants located within the IL1RL1 gene, 5 of which 
had genome-wide significant associations with sST2 concen-
trations, including rs6749114 (proxy for rs10192036, Q501K), 
rs4988956 (A433T), rs10204137 (Q501R), rs10192157 (T549I), 
rs10206753 (L551S), and rs1041973 (A78AE). Base substitutions 
and corresponding amino acid changes for these coding muta-
tions are listed in Table 3. In combination, these 6 missense muta-
tions accounted for 5% of estimated heritability, with an effect 
estimate of 0.23 (standard error [s.e.] 0.02, P = 2.4 × 10–20). When 
comparing major homozygotes with minor homozygotes, the esti-
mated sST2 concentrations for these missense variants differed 
by 11% to 15% according to genotype (Supplemental Table 5). 
In conditional analyses, intracellular and extracellular variants 
appeared to be independently associated with sST2. For instance, 
in a model containing rs4988956 (A433T) and rs1041973 
(A78E), both SNPs remained significantly associated with sST2 
(P = 2.61 × 10–24 and P = 7.67 × 10–15, respectively). In total, missense vari-
Figure 1
Regional association plot of sST2 SNPs with P < 5 × 10–8. “CEU” refers to Utah residents with northern and western European ancestry from the 
CEPH collection. Recombination rates are superimposed in blue, and gene regions are in green.
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ants added little to the proportion of sST2 variance explained by the 
11 genome-wide significant nonmissense variants listed in Table 1. 
In relating these 6 missense variants to other clinical phenotypes in 
large consortia, we found an association with asthma for 4 out of 
the 6 variants (lowest P = 4.8 × 10–12 for rs10204137) (25).
Homology map of IL1RL1 missense variants and ST2 structure. Of the 
6 missense variants mapping to IL1RL1, 5 were within the cytoplas-
mic Toll/IL-1R (TIR) domain of the transmembrane ST2 receptor 
(Figure 2A), and these intracellular variants are thus not part of 
the circulating sST2 protein. Of these cytoplasmic domain variants, 
A433T was located within the “box 2” region of sequence conserva-
tion, described in the IL-1R1 TIR domain as important for IL-1 sig-
naling (26). Q501R/K was within a conserved motif called “box 3,” 
but mutants of IL-1R1 in box 3 did not significantly affect IL-1 
signaling in previous experiments (26). Both T549I and L551S were 
near the C terminus of the transmembrane ST2 receptor and were 
not predicted to alter signaling function based on previous exper-
iments with the IL-1R (26). The A78E SNP was located within the 
extracellular domain of ST2 and is thus present in both the sST2 
isoform and the transmembrane ST2 receptor. In models of the 
ST2/IL-33/IL-1RAcP complex derived from a crystal structure of 
the IL-1RII/IL-1β/IL-1RAcP complex (protein data bank ID 1T3G 
and 3O4O), A78E was predicted to be located on a surface loop 
within the first immunoglobulin-like domain (Figure 2B), distant 
from the putative IL-33 binding site or the site of interaction with 
IL-1RAcP. There were 2 rare extracellular variants that were not cap-
tured in our GWAS due to low minor allele frequencies (A80E, MAF 
0.008; A176T, MAF 0.002). Both were distant from the IL-33 bind-
ing site on homology mapping and unlikely to affect IL-33 binding.
Functional effects of IL1RL1 missense variants on sST2 expression and 
promoter activity. Since 5 of the IL1RL1 missense variants asso-
ciated with sST2 levels mapped to the intracellular domain of 
ST2L and hence are not present on sST2 itself, we hypothesized 
that these missense variants exert effects via intracellular mecha-
nisms downstream of ST2 transmembrane receptor signaling to 
regulate sST2 levels. To investigate the effect of IL1RL1 missense 
variants (identified by GWAS) on sST2 expression, stable cell 
lines expressing WT ST2L, IL1RL1 variants (A78E, A433T, T549I, 
Figure 2
Models of ST2 illustrate IL1RL1 
missense variant locations. Models 
of the (A) intracellular TIR domain 
(ST2-TIR) and the (B) extracellular 
domain (ST2-ECD) of ST2 (protein 
data bank codes 3O4O and 1T3G, 
respectively). Domains of ST2 are 
shown in yellow, with identified mis-
sense SNP positions represented 
as red spheres and labels. Note that 
positions 549 and 551 are near the 
C terminus of ST2, which is not 
defined in the crystal structure (protein 
data bank ID 1T3G, shown as dashed 
black line in A). Arrows point toward 
the transmembrane domain, which is 
also not observed in crystal structures.
Table 3
Putative functional variants with at least suggestive association with sST2
Chr nSNP  Position Gene Allele Amino acid MAF βA s.e. P 
 (or proxy)  (NCBI 36.3) (major/minor) change
2 rs6749114B 102334019 IL1RL1 A/C Q501K 0.38 0.08 0.01 3.54E-17
2 rs4988956 102334439 IL1RL1 G/A A433T 0.38 0.08 0.01 3.66E-17
2 rs10204137 102334644 IL1RL1 A/G Q501R 0.38 0.08 0.01 3.66E-17
2 rs10192157 102334788 IL1RL1 C/T T549I 0.38 0.08 0.01 4.06E-17
2 rs10206753 102334794 IL1RL1 T/C L551S 0.38 0.08 0.01 4.33E-17
2 rs1041973 102321900 IL1RL1 C/A A78E 0.26 –0.05 0.01 2.15E-07
2 rs1014286 102515532 SLC9A4 A/G G784S 0.36 0.11 0.01 2.61E-33
2 rs2241132B 102170467 IL1RL2 C/A A124G 0.10 –0.13 0.02 2.68E-15
2 rs2302612 102218140 IL1RL2 T/C L550P 0.17 –0.08 0.01 2.08E-11
6 rs3799854B 46907968 MEP1A T/C T726M 0.38 –0.04 0.01 4.18E-05
6 rs2274658 46909030 MEP1A G/T V469L 0.40 –0.04 0.01 5.82E-05
1 rs1009668 224107027 TMEM63A C/T V622M 0.09 –0.06 0.02 8.22E-05
 
MEP1A, meprin A, α; TMEM63A, transmembrane protein 63A. Aβ estimate represents estimated change in log-sST2 per minor allele. BSNPs listed here 
are proxies for nSNP in 1000 Genomes Pilot 1 data set (rs6749114 serves as proxy for nSNP 10192036 [r2 = 1.0]; rs2241132 serves as proxy for nSNP 
rs2228139 [r2 = 0.75]; rs3799854 serves as proxy for nSNP rs1804211 [r2 = 1.0]). Pairwise linkage disequilibrium for SNPs listed in the table: rs6749114, 
rs4988956, rs10204137, rs10192157, rs10206753 (r2 = 1.0 for all); rs1804211 and rs2274658 (r2 = 0.9).
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Q501K, Q501R, and L551S), and a construct containing the 
5 IL1RL1 intracellular domain variants (5-mut) were generated. 
Expression of ST2L mRNA and protein (detected in membrane 
fractions) was confirmed (Supplemental Figures 5 and 6). Eight 
different stable clones in each group were analyzed to reduce 
bias from clonal selection.
Intracellular domain variants (A433T, T549I, Q501K, Q501R, 
L551S, and 5-mut), but not the extracellular domain variant 
(A78E), were associated with increased basal sST2 expression 
when compared with WT expression (P < 0.05 for all, Figure 3A). 
sST2 expression was highest in the 5-mut construct, suggesting 
that intracellular ST2L variants cooperatively regulate sST2 levels. 
This same pattern was consistent across different cell types (U937, 
Jurkat T, and A549 cells; Supplemental Figure 7). These findings 
suggest that intracellular domain variants of the transmembrane 
ST2 receptor may functionally regulate downstream signaling.
IL1RL1 transcription may occur via two alternative promoters 
(proximal vs. distal), which leads to differential expression of 
the soluble versus membrane-bound ST2 proteins (1). Similar 
to the sST2 protein expression results above, the intracellular 
domain variants, but not the extracellular domain variant, were 
associated with higher basal proximal promoter activity. Dis-
tal promoter activity was also increased for most intracellular 
domain variants (Supplemental Figure 8).
IL1RL1 intracellular missense variants resulted in higher IL-33 pro-
tein levels. In addition to upregulation of sST2 protein levels, 
IL1RL1 intracellular missense variants caused increased basal 
IL-33 protein expression (Figure 3B), suggesting a possible 
autoregulatory loop whereby IL-33 signaling positively induces 
sST2 expression. IL-33 induced sST2 protein expression in cells 
expressing both WT and IL1RL1 missense variants. Interest-
ingly, this effect was particularly pronounced in the A433T and 
Q501R variants (Supplemental Figure 9A).
Enhanced IL-33 responsiveness is mediated by IL-1β in A433T and 
Q501R variants. Because IL-1β can induce sST2 (27), we hypothe-
sized that IL-1β may increase IL-33 responsiveness in the A433T 
and Q501R variants. The addition of exogenous IL-1β induced 
sST2 protein expression in all IL1RL1 variants with no difference 
compared with WT cells (Supplemental Figure 9B). However, basal 
IL-1β levels were only elevated in A433T, Q501R, and 5-mut con-
structs (Figure 3C). Further, preincubation with anti–IL-1β mAb 
eliminated the enhanced IL-33 responsiveness in A433T, Q501R, 
and 5-mut variants (P < 0.05, Figure 3D). Last, induction of sST2 
by IL-33 was blocked by anti-ST2 mAb (P < 0.05, Supplemental 
Figure 10). These findings indicate that IL-33–induced sST2 
expression in A433T and Q501R is mediated through IL-1β and 
transmembrane ST2 receptor signaling.
Interaction among IL-33, sST2, and IL-1β. We further determined 
Figure 3
IL1RL1 intracellular missense variants resulted in higher sST2 and IL-33. Media from KU812 cells expressing WT and IL1RL1 missense variants 
were collected for ELISA analysis of (A) sST2, (B) IL-33, and (C) IL-1β levels. Horizontal bars indicate mean values, and symbols represent indi-
vidual variants. *P < 0.05, **P < 0.01 vs. WT. (D) Effect of anti–IL-1β mAb on IL-33–induced sST2 expression. Dashed line indicates PBS-treated 
cells as referent group. Error bars represent mean ± SEM from 2 independent experiments. *P < 0.05 vs. IL-33.
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the interaction of IL-33, sST2, and IL-1β in the regulatory loop. 
Inhibition of IL-1β by anti–IL-1β mAb reduced basal expression 
of sST2 (Supplemental Figure 11A). Blocking of IL-33 by sST2 did 
not reduce the induction of IL-1β levels by the IL1RL1 variants 
(Supplemental Figure 11B). Furthermore, inhibition of IL-1β by 
anti–IL-1β reduced the basal IL-33 levels. IL-33 itself upregulated 
sST2 levels, which in turn reduced IL-33 levels (Supplemental 
Figure 11C). Our results revealed that both IL-33 and IL-1β drive 
sST2 expression and that IL-1β acts as an upstream inducer of 
IL-33 and maintains IL-33 expression by intracellular IL1RL1 vari-
ants (Supplemental Figure 11D). This suggests that IL1RL1 vari-
ants upregulated sST2 mainly through IL-33 autoregulation and 
that the enhanced IL-33 responsiveness by A433T and Q501R was 
mediated by IL-1β upregulation.
IL1RL1 missense variants modulate ST2 signaling pathways. The effect 
of IL1RL1 missense variants on known ST2 downstream regulatory 
pathways, including NF-κB, AP-1/c-Jun, AKT, and STAT3 (28–32), 
was examined in the presence and absence of IL-33 (Figure 4 and 
Supplemental Figure 12). The IL1RL1 intracellular missense vari-
ants (A433T, T549I, Q501K, Q501R, and L551S) were associated 
with higher basal phospho–NF-κB p65 and phospho–c-Jun levels 
(Figure 4, A and B). Consistent with enhanced IL-33 responsive-
ness in A433T and Q501R cells, levels of IL-33–induced NF-κB and 
c-Jun phosphorylation were enhanced in these 2 variants (Figure 4, 
B and D). In contrast, A433T and Q501R variants showed lower 
basal phospho-AKT levels (Figure 4E). IL-33 did not directly reg-
ulate AKT activation, since phospho-AKT levels were not affected 
with or without IL-33 stimulation (Figure 4F). IL1RL1 missense 
variants did not affect STAT3 signaling (Supplemental Figure 12). 
These results reveal increased activation of basal NF-κB and 
AP-1 associated with upregulation of sST2 expression by IL1RL1 
intracellular variants. In addition, reduced AKT signaling by 
A433T and Q501R variants might be associated with enhanced 
IL-33 responsiveness.
We also found that inhibition of NF-κB and AP-1 reduced IL1RL1 
proximal promoter activity, whereas distal promoter activity was 
inhibited by AP-1 blockade but not NF-κB inhibition. This suggests 
that both NF-κB and AP-1 are important for proximal promoter 
activation and that AP-1 is important for distal promoter activation 
by the intracellular IL1RL1 variants (Supplemental Figure 13).
Mal and MYD88 are required for intracellular IL1RL1 variant–induced 
sST2 expression. We also analyzed the subcellular localization of 
ST2L in IL1RL1 variants. ST2L was detected predominantly in 
the membrane fraction, and sST2 was detected in the cytosol frac-
tion. The intracellular IL1RL1 variants upregulated cytosolic sST2 
levels as well as the sST2 levels in the culture media. In addition, 
A433T and Q501R caused higher membrane ST2L expression 
(Supplemental Figure 6). To test the possibility that IL1RL1 vari-
ants interact with Mal, MYD88, and the PI3K subunit, we per-
formed coimmunoprecipitation assays and found that all of the 
IL1RL1 variants interacted with Mal and MYD88. In addition, bind-
ing of Mal to ST2L was increased by the intracellular variants. Only 
Figure 4
IL1RL1 missense variants modulated ST2 signaling pathways. KU812 cells expressing WT or IL1RL1 variants were treated with PBS or IL-33. 
Levels of the following phosphorylated proteins were detected in cell lysates using ELISA: (A and B) phospho-NF-κB p65; (C and D) phospho- 
c-Jun activity; and (E and F) phospho-AKT. (A, C, and E) White bars represent basal levels, and (B, D, and F) gray bars represent relative fold 
increase (compared with PBS-treated group) after IL-33 treatment. *P < 0.05 vs. WT; **P < 0.01 vs. PBS-treated group. Dashed line in B, D, and 
F represents PBS-treated cells as referent group. Error bars represent mean ± SEM from 2 independent experiments.
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A433T and Q501R interacted with the PI3K-p85 subunit, indicat-
ing that these 2 IL1RL1 variants may regulate the PI3K/AKT sig-
naling pathway through the interaction of the ST2L intracellular 
domain with the PI3K-p85 subunit (Supplemental Figure 14).
We further examined the role of Mal, MYD88, and PI3K-p85 
in sST2 induction by IL1RL1 variants. Knockdown of Mal and 
MYD88 by siRNA completely inhibited sST2 induction by 
intracellular IL1RL1 variants, indicating that Mal and MYD88 
are necessary for ST2L-mediated sST2 induction. Knockdown of 
PI3K-p85 had no effect on IL-33–induced sST2, whereas knock-
down of PI3K-p85 blocked A433T, Q501R, and 5-mut–enhanced 
IL-33 responsiveness (Supplemental Figure 15). These results sug-
gest that the increased binding of Mal to the ST2L intracellular 
domain mediates sST2 expression seen in intracellular IL1RL1 
variants. Furthermore, the recruitment of PI3K-p85 to A433T and 
Q501R mediates the enhanced IL-33 responsiveness.
IL-33–induced sST2 expression is reciprocally regulated by different 
signaling pathways. IL1RL1 intracellular variants caused increased 
basal activation of NF-κB and AP-1 and lower basal AKT phos-
phorylation in A433T and Q501R variants (Figure 4). We hypoth-
esized that sST2 is reciprocally regulated by NF-κB, AP-1, and AKT 
pathways, and thus we investigated the role of PI3K/AKT/mTOR, 
ERK/NF-κB, and JNK/AP-1 pathways on IL-33–induced sST2 
expression. Inhibitors of PI3K and mTOR further enhanced 
IL-33–induced sST2 expression (Figure 5A). In contrast, inhib-
itors of ERK, JNK, NF-κB, and AP-1 abrogated IL-33–induced 
sST2 expression, indicating that NF-κB and AP-1 are required 
for IL-33–induced sST2 expression (Figure 5A). These data 
Figure 5
IL-33–induced sST2 expression is enhanced with mTOR inhibition and occurs via ST2L-dependent signaling. (A) sST2 mRNA expression in KU812 
cells after treatment with DMSO, IL-33, or IL-33 plus signal inhibitors (wortmannin, LY294002, rapamycin, PD98059, SP60125, BAY11-7082, or 
SR11302). (B) ST2L mRNA and (C) sST2 mRNA expression in KU812 cells treated with PBS (white columns), rapamycin (rapa), anti-ST2 mAb, 
IL-33, IL-33 plus anti-ST2, IL-33 plus rapamycin, IL-33 plus rapamycin plus anti-ST2 mAb, or rapamycin plus anti-ST2. (D) IL33 mRNA expression in 
KU812 cells after treatment with DMSO, signal inhibitors, IL-33 plus signal inhibitors, and IL-1β plus signal inhibitors. *P < 0.05 vs. PBS-treated group; 
#P < 0.05 vs. IL-33–treated group; &P < 0.05 vs. IL-1β–treated group. Error bars represent mean ± SEM from 2 independent experiments. 
(E) A schematic model illustrating the regulation of sST2 expression by IL1RL1 missense variants through enhanced induction of IL-33 via 
enhanced NF-κB and AP-1 signaling and enhanced IL-33 responsiveness via increasing ST2L expression.
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reveal reciprocal regulation of IL-33–induced sST2 expression by 
PI3K/AKT/mTOR, ERK/NF-κB, and JNK/AP-1 pathways.
Inhibition of the PI3K/AKT/mTOR axis increases IL-33 responsiveness 
and sST2 expression through IL-1β–mediated ST2L induction. Rapamy-
cin has been shown to trigger ST2L expression through upregulat-
ing IL-1β (30). We found that inhibition of mTOR with rapamycin 
specifically induced ST2L but not sST2 expression in the absence 
of IL-33 (Figure 5, B and C). This effect was blocked by anti–IL-1β 
mAb, suggesting that IL-1β mediated rapamycin-triggered ST2L 
expression (Figure 5B). In addition, rapamycin enhanced IL-33–
induced sST2 expression, an effect that was blocked by anti–IL-1β 
and anti-ST2 (Figure 5C). These results suggest that inhibition of the 
PI3K/AKT/mTOR axis can increase IL-33 responsiveness via IL-1β–
triggered endogenous ST2L expression. This may be the underlying 
mechanism of enhanced IL-33 responsiveness in the A433T and 
Q501R variants, in which we found reduced AKT signaling.
NF-κB and AP-1 are required for IL-33 expression. To determine 
the mechanism for increased IL-33 expression in the presence of 
IL1RL1 intracellular variants, we examined the role of PI3K/AKT, 
NF-κB, and AP-1 in the regulation of IL-33 expression. Inhibition 
of PI3K, NF-κB, and AP-1 reduced basal IL-33 expression (P < 0.05; 
Figure 5D). IL33 mRNA expression was induced by IL-1β and IL-33 
itself (P < 0.05), which in turn was blocked by inhibition of NF-κB 
and AP-1 but not affected by inhibition of PI3K/AKT. This indi-
cated that NF-κB, AP-1, and PI3K/AKT signals are required for 
basal IL-33 expression, whereas only NF-κB and AP-1 are necessary 
for IL-33 induction after IL-1β and IL-33 stimulation.
In summary, our experiments demonstrate that IL-33 induces 
sST2 expression through NF-κB and AP-1 and that the IL1RL1 
intracellular domain variants regulate IL-33–induced sST2 
expression via 2 mechanisms: (a) enhanced induction of IL-33 
via enhanced NF-κB and AP-1 signaling and (b) enhanced IL-33 
responsiveness via increasing ST2L expression (Figure 5E).
Discussion
Our findings indicate that genetic factors account for up to 40% of 
the interindividual variability in circulating sST2 concentrations. 
This substantially exceeds the amount of variation in sST2 attrib-
utable to measured clinical and environmental factors (~14%), 
although this may be underestimated due to unmeasured clinical 
factors. Common genetic variants within or near the IL1RL1 gene 
alone accounted for more than 10% of the phenotypic variation in 
sST2, nearly as much as all measured clinical variables together. 
We mapped intracellular IL1RL1 missense variants associated with 
circulating sST2 concentrations in our GWAS to the TIR domain, 
a region important in downstream signaling. In molecular func-
tion studies, we demonstrate that these IL1RL1 missense variants 
expressed in membrane-bound ST2 (ST2L) but not expressed in 
its soluble form (sST2) can induce sST2 expression and that this 
occurs via a direct effect on ST2L expression and downstream sig-
naling. Thus, genetic variants that change intracellular ST2 trans-
membrane signaling can induce human sST2, revealing a new 
pathway in immune and inflammatory regulation.
The ST2/IL-33 pathway plays a major role in immune and 
inflammatory responses by inducing Th2 immune responses (2, 3). 
Clinically, ST2 appears to contribute to the pathophysiology of 
a number of inflammatory and immune diseases related to Th2 
activation, including asthma (5), ulcerative colitis (6), and inflam-
matory arthritis (7). Additionally, ST2 is emerging as an impor-
tant mediator of cardiac remodeling as well as a valuable prog-
nostic marker in cardiovascular disease (11–13, 15, 17, 33, 34). 
Understanding the genetic determinants of sST2 may lend impor-
tant insights into regulation of the sST2 pathway and may lead 
to the discovery of novel therapeutic targets for the treatment of 
immune and cardiovascular disease.
The majority of sST2 gene variants in our study were located 
within or near IL1RL1, the gene coding for both transmembrane 
ST2 and sST2. IL1RL1 resides within a linkage disequilibrium 
block of 400 kb on chromosome 2q12, a region that includes a 
number of other cytokines, including IL-18 receptor 1 (IL18R1) 
and IL-18 receptor accessory protein (IL18RAP). Polymorphisms 
in this gene cluster have been associated previously with a num-
ber of immune and inflammatory conditions, including asthma 
(35), celiac disease (36), and type 1 diabetes mellitus (37). Many 
of these variants were associated with sST2 concentrations in our 
analysis (Supplemental Table 6). The immune effects of ST2 are 
corroborated by experimental evidence: membrane-bound ST2 is 
selectively expressed on Th2- but not Th1-type T helper cells, and 
activation of the ST2/IL-33 axis elaborates Th2 responses (2, 3). 
In general, the allergic phenotypes above are thought to be Th2-
mediated processes, in contrast to atherosclerosis, which appears 
to be a Th1-driven process (38).
How these genetic variants differentially relate to these previ-
ously described immune and inflammatory diseases compared 
with cardiovascular disease is unknown. We found 2 variants with 
suggestive associations with clinical phenotypes. The directional-
ity suggests that variants with lower sST2 concentrations may be 
associated with higher C-reactive protein and adverse outcomes, 
but these data should be considered hypothesis generating. This 
association is counter to clinical observations, in which higher 
sST2 concentrations were associated with adverse outcomes (19). 
Experimental data support an overall protective effect of IL33/ST2 
signaling; activation of membrane-bound ST2L by IL33 leads to 
reduced hypertrophy and fibrosis (9). The genetic variants studied 
in our manuscript are located in membrane-bound ST2L, and we 
show that genetic variants in membrane-bound ST2L enhance both 
sST2 expression and also IL-33 responsiveness of ST2L itself. Thus, 
genetic variants likely influence both soluble and membrane-bound 
ST2. It may be that increased expression of ST2 reflects a compen-
satory response to cardiac stress, as seen with other molecules (such 
as BNP), in which the association of genetic variants with outcomes 
has the opposite directionality from circulating levels (39). We 
found strong evidence linking IL1RL1 genotypes with soluble ST2; 
on the other hand, the associations with clinical outcomes warrant 
further confirmation. Furthermore, because variants in this region 
are in high linkage disequilibrium, it is not possible to determine 
whether the effect is due solely to variants in IL1RL1 or neighboring 
loci within the linkage disequilibrium block, and identification of 
other causal variants requires additional study.
To our knowledge, our study is the first investigation to demon-
strate associations between ST2 genotype and circulating human 
sST2 concentrations. We extended findings to in silico tissue 
expression: rs13001325 was associated with both sST2 concen-
trations and IL1RL1 gene expression in brain tissue. The direc-
tionality of the association was consistent among genotype, gene 
expression, and sST2 concentrations, lending additional weight to 
this finding. These data are consistent with prior gene expression 
studies, demonstrating significant sST2 mRNA levels in brain tis-
sue compared with that in other organs (40).
We explored potential functional consequences of sST2 missense 
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variants in our GWAS first by homology mapping the variants to 
the IL-1R. The A78E variant mapped to the surface of sST2 and 
extracellular ST2L domain, with the side chain oriented toward 
the hydrophobic protein interior and, based on homology with 
the IL-1β receptor, would be unlikely to disrupt the IL-33 binding 
site. Of the remaining 5 IL1RL1 coding mutations, 4 mapped to the 
TIR domain on membrane-bound ST2, an intracellular signaling 
domain common to all Toll and IL-1Rs. The A433T variant would 
be predicted to have the highest probability of directly influencing 
TIR domain–mediated signaling by ST2. This variant was located 
in “box 2,” a region predicted by in silico docking studies to facil-
itate protein-protein interactions with the TIR domains of the 
adaptor proteins myeloid differentiation primary response gene 88 
(MyD88) and MyD88 adaptor-like (Mal), leading to expression of 
proinflammatory cytokines (41).
In order to elucidate the functional consequences of these IL1RL1 
nSNPs, we examined the effect of each of these missense muta-
tions on sST2 expression in experimental studies. The extracellular 
A78E variant did not alter sST2 expression, suggesting that IL-33 
binding to the extracellular ST2L domain was not altered by 
this variant. All other intracellular variants were associated with 
increased sST2 expression, indicating that signal transduction via 
the ST2L intracellular domain plays an important role in regulat-
ing sST2. This occurs via alterations in ST2 signaling pathways, 
including transcription factors NF-κB and AP-1 (28, 29), which 
are known to regulate sST2 expression, and the PI3K/AKT/mTOR 
pathway, which is known to regulate ST2L expression (30). The 
A433T and Q501R variants specifically demonstrated enhanced 
sST2 expression after IL-33 induction, which was blocked by both 
anti-ST2L mAb and anti–IL-1β. This suggests that mTOR-medi-
ated ST2L expression contributes to increased IL-33–induced sST2 
expression observed in these variants. Interestingly, while Q501R 
and Q501K variants both result in positively charged amino acid 
substitutions, they have differential effects on signaling pathways. 
Q501R but not Q501K inhibited the PI3K/AKT/mTOR pathway 
and increased IL-33 responsiveness through increasing endoge-
nous ST2L expression. Furthermore, we found that A433T and 
Q501R interact with the PI3K-p85 subunit and may regulate AKT 
signaling by modulating the interaction of the ST2L TIR domain 
with other receptor tyrosine kinase or PI3K subunits (32, 42).
Due to the high degree of linkage disequilibrium at the IL1RL1 
locus, it is not possible to determine where the true signal origi-
nates using population-based data. However, these experimental 
findings suggest that missense variants underlie, at least in part, 
the genetic determinants of sST2 concentrations. We found other 
sST2 variants located in neighboring genes within the 400-kb link-
age disequilibrium block but not within the IL1RL1 locus. These 
variants could theoretically contribute to ST2 regulation via trans 
effects and will need further study. Given our focus on common 
variants, we expect that other variants may influence ST2 concen-
trations, each with a small-to-modest effect size.
A recent study showed that deletion of the proximal ST2 pro-
moter disrupts fibroblast-specific sST2 expression but does 
not affect serum sST2 levels (43). These results may be rec-
onciled with our findings by considering that ST2 promoter 
usage appears to be highly cell-type dependent and that fibrob-
lasts may not be the major source of circulating sST2. Human 
endothelial cells, immune cells, and lung epithelial cells are 
known to express high levels of sST2 and might be the major 
source of circulating sST2 (40, 44). We found that IL1RL1 
intracellular variants associated with higher sST2 concentra-
tions on a population level were also associated with higher 
sST2 protein levels in KU812 human basophils as well as in 
A549, U937, and Jurkat T cells. This suggests that the regula-
tion of sST2 expression by IL1RL1 missense variants can occur 
in human immune and epithelial cells.
Several limitations deserve mention. The relative contributions 
of clinical and genetic factors to variation in sST2 are estimates, 
and clearly unmeasured factors not included in our analysis may 
also influence sST2 concentrations. Specifically with regards to 
heritability estimates, the influence of shared genes and shared 
environmental exposures is often difficult to distinguish. How-
ever, we found no significant correlation of sST2 concentrations 
among spousal pairs, which suggests that shared environmental 
factors are probably less important.
In summary, our findings demonstrate substantial heritability 
of sST2 concentrations and identify a robust association with 
genetic variants within or near the IL1RL1 gene. In molecular stud-
ies, IL1RL1 missense variants identified using a population-based 
approach induced sST2 expression via direct effects on ST2L sig-
naling and modulation of ST2 promoter activity. Studies elucidat-
ing the functional consequences of genetic variation in sST2-re-
lated genes may lead to a better understanding of the ST2 pathway 




The FHS Offspring study is a prospective, observational, community
-based study (45). Children (and spouses of the children) of FHS original 
cohort participants were recruited in 1971 and have since been followed 
with serial examinations. Soluble ST2 concentrations were measured on 
stored frozen blood specimens collected at the sixth examination cycle 
(1995–1998). A total of 2,991 participants were included in this analysis.
Laboratory testing
Blood samples collected after an overnight fast were centrifuged for stor-
age at –70°C. sST2 concentrations were measured using a high-sensitivity 
sandwich immunoassay (Presage ST2; Critical Diagnostics) (46). The assay 
is stable over time and has a lower detection limit of 2 ng/ml. Within-run 
and total coefficients of variation are ≤2.5% and ≤4.0%, respectively (46).
Genome-wide genotyping and imputation
Genotyping was conducted using the Affymetrix 500K mapping array 
and the Affymetrix 50K gene-focused MIP array (dbGaP study acces-
sion phs000342.v7.p7). Genotypes from the Affymetrix 500K mapping 
array were called using Chiamo (47). For imputation of genotypes to the 
HapMap set of 2.5 million SNPs (CEU population, release 22, build 36; 
http://hapmap.org), a hidden Markov model was used, as implemented 
in MACH (version 1.0.15) (48).
In silico association of genetic variants with gene expression, clinical 
outcomes, and other cardiovascular biomarkers
The top 10 sST2 SNPs with pairwise r2 < 0.2 were searched against a col-
lected database of expression SNPs (eSNPs) to examine relations with cis 
gene expression levels across different tissue types (Supplemental Meth-
ods). Because circulating ST2 concentrations are associated with mor-
tality and cardiovascular events, we performed look-ups in large GWASs 
for association of sST2 genetic variants with these clinical outcomes in 
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a forward selection regression model was used, with P < 0.05 for entry 
(details in the Supplemental Methods). Analyses were performed using 
SAS, version 9.1.3 (SAS Institute).
Heritability. Variance-component models were used to estimate the 
heritability of sST2 using Sequential Oligogenic Linkage Analysis Rou-
tines (50). Heritability estimates were age and sex adjusted and also 
multivariable adjusted (age, sex, systolic blood pressure, antihyperten-
sive medication use, diabetes mellitus, and smoking status). Clinical 
covariates suspected to be potential confounders were selected based 
on prior studies (13, 34, 51). Secondary analyses are detailed in the Sup-
plemental Methods.
GWAS. Associations of genetic variants and sST2 concentrations were 
tested using linear mixed-effects models to accommodate pedigree data 
under an additive genetic model, with covariates used for heritability 
analysis. Genome-wide association analyses were performed using R (52) 
and implemented using the lmekin function in the kinship package (53). 
Results were considered genome-wide significant at P < 5 × 10–8. Soluble 
ST2 concentrations (back transformed from log-transformed data) were 
estimated by genotype for the top SNP.
Study approval
Participants provided informed consent, and the study was approved by 
the Institutional Review Board at Boston University Medical Center.
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the CHARGE (22) and CARDIoGRAM consortia (details in the Supple-
mental Methods) (23).
Comparative modeling of ST2 and missense variants. Homology model-
ing of the ST2 protein structure was used to analyze missense variants 
using SWISS-MODEL (49). Crystal structures of either the T1R domain 
of IL-1R–associated protein (IL-1RAcP, protein data bank ID 1T3G) or 
IL-1R type II (IL-1RII) bound to IL-1β and IL-1RAcP (protein data bank 
ID 3O4O) were used as templates for models of ST2.
Cell culture studies
Cloning and plasmids. For details, please see the Supplemental Methods. 
In brief, the human basophil cell line KU812 was maintained in RPMI 
1640 (Invitrogen) containing 10% FBS. HEK293 cells were cultured in 
DMEM (Invitrogen) containing 10% FBS. Full-length WT human ST2L 
was obtained via RT-PCR from KU812 cDNA. pCR-Blunt II Topo vec-
tor (Invitrogen) was used as intermediate vector. Mutations were intro-
duced using PCR-based mutagenesis. Full-length ST2L cDNA was then 
subcloned into pCDH-CMV-MCS-EF1-GFP-T2A-Puro lentiviral vector 
(System Biosciences). All constructs were verified by DNA sequencing.
Lentivirus preparation and cell line creation. Lentiviral constructs were 
introduced with psPAX and pMD2.G packaging and envelope vectors into 
293TN cells. Culture media were harvested after 72 hours, and lentiviral 
particles were concentrated by ultracentrifugation (if destined for in vivo 
delivery) or Peg-IT reagent (if destined for cell line creation). Stable cell 
lines were created by transducing KU812 cells with concentrated lenti-
virus and subsequent puromycin selection by limited dilution in 96-well 
plates. IL1RL1 variant constructs were generated using PCR-based muta-
genesis. The 5-mut construct has a minor variant on codon Q501 with 
CAG to AGG (Q501R) and encodes ST2L protein containing variants 
A433T, T549I, Q501R, and L551S. Expression was confirmed via Western 
blotting for ST2 and/or His-taq as appropriate.
ST2 promoter constructs and promoter assays. We used PCR with specific prim-
ers to amplify the different regions upstream of exon 1a (distal) and exon 
1b (proximal) of the human IL1RL1 gene from the DNA of the BAC clone 
(RP11-315O22). ST2 proximal and distal promoters fragments containing 
different lengths of sequences were inserted between the SacI and NheI sites 
of the pGL3-basic vector (Promega) containing the entire coding sequences 
of firefly luciferase with specific primers. For ST2 promoter assays, KU812 
cells expressing ST2L variants were transfected by using Purefection (Sys-
tem Biosciences) with 500 ng of plasmids. After 24-hour incubation, cells 
were harvested in lysis buffer and assayed for luciferase activity.
Real-time PCR. Total RNA was isolated using TRIzol reagent (Invitrogen). 
cDNA was synthesized from 1 μg of total RNA and random hexamers 
using the TaqMan Reverse Transcription Kit (Applied Biosystems). Real-
time PCR was performed in a 7300 Real-Time PCR system (Applied Bio-
systems). All reactions were performed in duplicate. The relative amount 
of sST2, ST2L, or IL33 mRNA was normalized to HPRT.
ELISA. For basal sST2 protein expression level analysis, KU812 cells 
expressing WT or IL1RL1 variants were cultured in serum-free RPMI 1640 
medium for 24 hours. The media were collected for ELISA analysis for 
sST2 (Presage ST2, Critical Diagnostics), IL-1β (R&D System), and IL-33 
(R&D System). For signal activation analysis, cells were subjected to serum 
starvation for 8 hours and then treated with PBS or IL-33 for 30 minutes. 
Cell lysates were for ELISA detection (Cell Signaling Technology) of phos-
pho–NF-κB p65 (Ser536), phospho–c-Jun (Ser63), phospho-AKT (Thr308), 
and phospho-STAT3 (Tyr705).
Statistics
Soluble ST2 concentrations were log transformed due to right-skewed 
distribution. To examine the association of sST2 with clinical covariates, 
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